These 4 Singaporean companies are changing healthcare as we know it
These 4 Singaporean companies are changing healthcare as we know it
Healthcare (HC)
Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics
MAY 26, 2021 – SINGAPORE & SAN CARLOS, Calif.–Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions.
Hummingbird Bioscience Raises US$125 Million in Series C Financing
SINGAPORE, May 17, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced the close of its US$125 million Series C financing round.
ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery
SINGAPORE and SAN DIEGO – April 14, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, today announced it has completed a $14 million fundraising round co-led by new investor EDBI together with existing investors Anzu Partners and University of Tokyo Edge Capital Partners (UTEC).
Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Company concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.
Singapore-headquartered telehealth start-up Doctor Anywhere closes US$27 million Series B Financing led by Square Peg, EDBI and IHH
SINGAPORE – 31 March 2020 – Doctor Anywhere , a regional tech-led healthcare company headquartered in Singapore, announced today that it has secured a US$27 million Series B financing round led by Square Peg – the largest venture capital fund in Australia, Singapore Government investment arm – EDBI, and IHH Healthcare, a leading international healthcare provider. Rounding out this series of funding are Pavilion Capital and existing shareholder Kamet Capital, bringing Doctor Anywhere’s total capital base to exceed US$40 million.
ElevateBio Closes $170 Million Series B Financing
Cambridge, Mass. – March 30, 2020 – ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, today announced it has closed a $170-million Series B financing that will support and accelerate the company’s next phase of growth.
eko.ai raises $4 million in funding, co-led by Sequoia India and EDBI, to automate the fight against heart disease
Singapore, Tuesday 7th January – eko.ai, a fast-growing medtech startup based in Singapore, has raised a $4 million USD round co-led by Sequoia India and Singapore government-linked strategic investor EDBI. Partech Ventures, SG Innovate and Startup Health Transformer also participated in the round.
Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer
Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer
Livongo Signs Definitive Agreement to Acquire myStrength to Address Behavioral Health Needs for People with Chronic Conditions
Livongo Signs Definitive Agreement to Acquire myStrength to Address Behavioral Health Needs for People with Chronic Conditions
